It's becoming apparent that a lot of researchers are interested in AT in a wide variety of disease states. Perhaps in part due to availability? I wonder if GTCB is selling or giving product to researchers. Or is all animal research using animal versions of AT? The plasma derived human version is scarce and expensive. The safety aspect of AT is very compelling, IMO. AT does not cause bleeding (when not potentiated by heparin); rather it prevents the clotting cascade from getting out of control and has the anti-inflammatory properties. I wonder how many disease states involve acquired AT deficiency. Does having higher than normal levels of AT on board confer any advantage or is it satisfactory to just maintain normal levels? For instance in the animal MI and stroke models - what happened to the AT levels before and after the insult? We know what happens in sepsis(with DIC) and burns and it seems to me giving AT is a no brainer there.
Market Data 
Markets 
AI
